University of Louisville-Originated Investigational Allogeneic Cell Therapy Demonstrating Improved Patient Quality of Life for LDKTs

University of Louisville-Originated Investigational Allogeneic Cell Therapy Demonstrating Improved Patient Quality of Life for LDKTs

Talaris Therapeutics, a privately held biotechnology company developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, presented data from a Phase 2 trial of its investigational...
Tackling T Cells: A Path to Hope

Tackling T Cells: A Path to Hope

Nancy Fleisler writing for Harvard Medical School reports on Harvard Medical School and Boston Children’s Hospital studies focused on T cells are a path toward reducing organ transplant rejection and treating autoimmune diseases. There are two kinds of T cells...

Pin It on Pinterest